Synopsis On November 11, last year, Dr VG Somani's term as DCGI was extended for three months, for the second time, coming into effect on November 16, 2022. ANI Rajeev Singh Raghuvanshi is new Drugs Controller General of India The appointment of Rajeev Raghuvanshi as the new Drug Controller General of India ( DCGI ) was approved by the Appointments Committee of the Cabinet on Wednesday, an official release stated. The Union Public Service Commission ( UPSC ) conducted interviews for the appointment of the DCGI in January, with the top contenders being Dr.
VG Somani, Dr Rajeev Singh Raghuvanshi, and Dr Jai Prakash. "The Union Public Service Commission on the basis of assessment of bio-data of the eligible officers received. .
. and after holding personal talks with them on January 27 recommend Dr Rajeev Singh Raghuvanshi for appointment to the post of Drug Controller (India) by short term contract basis," the UPSC communicated to the Health Ministry on January 30. Dr Somani was appointed DCGI for a term of three years on August 14, 2019 and he took charge on August 16.
His tenure was extended twice -- on August 16 and November 16 -- for three months each. The DCGI heads the Central Drugs Standard Control Organisation ( CDSCO ) which is responsible for ensuring quality drugs supply across the country. It also has authority to give approval to new drugs and regulating clinical trials.
Dr Raghuvanshi had joined the IPC as secretary-cum-scientific director on February 16, 2021. He completed his Bachelors and Masters from IIT-BHU (formerly IT-BHU), Varanasi and PhD from the National Institute of Immunology, New Delhi. After working for seven years at the National Institute of Immunology, he joined leading Indian multinational pharmaceutical company Ranbaxy Laboratories Ltd.
After 12 years at Ranbaxy Laboratories, he moved to Dr Reddy's Laboratories Ltd, Hyderabad, where he worked for 11 years. Dr Raghuvanshi's expertise lies in dosage form design and development, mainly in the domain of pharmaceutical innovation. He has been involved in development of different kind of products such as oral solids, oral liquids, topicals, injections, nasal sprays, auto-injectors, sublingual, mouth dissolve, extended release and delayed release for global markets.
More than 200 products developed by him and his teams are currently being sold in India, US, Europe and emerging markets. Dr Raghuvanshi has 14 granted US patents along with more than 250 published patent cooperation treaties and Indian patents. He has more than 25 publications in peer reviewed journals and has co-authored six chapters in books.
For his contribution, Dr Reddy's Labs has twice awarded him with "Dr Reddy's Excellence Award". Don’t miss out on ET Prime stories! Get your daily dose of business updates on WhatsApp. click here! Wednesday, 22 Feb, 2023 Experience Your Economic Times Newspaper, The Digital Way! Read Complete Print Edition » Front Page Pure Politics Brands & Companies Economy More On the Podium: Chartbuster Growth, Pandemic Heroes Bharti Enterprises chairman Sunil Bharti Mittal chosen as Business Leader of the Year, ICICI Bank as Company of the Year and health minister Mansukh Mandaviya as Business Reformer of the Year Sebi Seeks Details onRatings of Adani Cos’ Loans and Securities The Indian capital markets regulator has sought details of all ratings of local loans and securities of Adani group companies from credit rating firms.
‘Growth may have Come Down to About 5% in Q3’ India’s economic growth likely slumped to a median 5. 0% in the third quarter, its lowest this fiscal year, according to an ET poll of 11 economists. Forecasts ranged from 4.
3% to 5. 2%. An adverse base effect and mixed economic performance dragged growth down from 6.
3% in the second quarter, according to them. Read More News on DCGI News rajeev raghuvanshi drug regulatory body dcgi upsc cdsco Rajeev Raghuvanshi News (Catch all the Business News , Breaking News Events and Latest News Updates on The Economic Times . ) Download The Economic Times News App to get Daily Market Updates & Live Business News.
. . .
more less ETPrime stories of the day Artificial intelligence Privacy, transparency, recourse: developing a regulatory framework for AI that wins people’s trust 11 mins read 3 insights to kick-start your day, featuring Zuckerberg imitating Elon Musk 3 mins read Strategy Stock Radar: Breakout from a 9-month consolidation could take this services company to a fresh 52-week high; time to buy? 3 mins read Subscribe to ETPrime.
